Search NLS News

The company receives support from the Swedish Research Council’s major investment ENABLE-2, which in collaboration with Vinnova gives small and medium-sized companies access to the ENABLE-2 platform to continue development of new antibiotics. QureTech Bio is developing new drugs that either enhance the existing effects of antibiotics or disarm bacteria instead of killing them, thereby […]

Q&As with six Shimadzu specialists from Sweden. At the end of 2019, Shimadzu opened its own subsidiary in Sweden. It distributes Shimadzu’s full range of analytical instrumentation solutions, including chromatography, mass spectrometry, TOC (sum parameters) and spectroscopy, targeting clinical, pharmaceutical, environmental and food applications in industry and academia. Sales, service and application specialists work in […]

The Board of Directors of Targovax has signed a joint demerger and merger plan, respectively, for the transfer of the operational activities of the company to its wholly-owned subsidiary, Targovax Solution AS. The transfer is proposed carried out as a “drop-down demerger” where the company demergers operations and assets to its subsidiary Athomstart Invest 586 […]

The companies have signed a large-scale manufacturing agreement for the main drug intermediate in the supply of clinical material for Oasmia’s investigational drug candidate, Cantrixil. “We are excited to have partnered with Lonza, a global leader in drug manufacturing. The manufacture of Cantrixil is planned to be performed in three steps and this agreement is […]

Bavarian Nordic has entered into an exclusive license and supply agreement with Nuance Pharma, a Shanghai-based specialty pharmaceutical company. The agreement concerns the development and commercialization of MVA-BN RSV against respiratory syncytial virus (RSV) in adults in Chinese Mainland, Hong Kong, Macau, Taiwan, South Korea and certain Southeast Asian countries. The agreement entails clinical development, […]

The largest genetic study of migraine to date reveals new genetic risk factors. In the largest genome study of migraine yet, researchers have more than tripled the number of known genetic risk factors for migraine. Among the identified 123 genetic regions are two that contain target genes of recently developed migraine-specific drugs. The study involved […]

Researchers have developed a nasal spray to protect vulnerable people from not only COVID-19 but also from infection with several other viruses. The new treatment formulation that is being tested in a Phase 3 trial by the University of Cambridge in the United Kingdom. Morten Otto Alexander Sommer, one of the researchers behind the development […]

Alexion, AstraZeneca’s Rare Disease group, has entered into a settlement agreement with Chugai Pharmaceutical, resolving all patent disputes between the two companies related to Ultomiris (ravulizumab). In accordance with the settlement agreement, Alexion and Chugai have taken steps to withdraw patent infringement proceedings filed with US District Court for the District of Delaware and Tokyo […]

Ilya Pharma has closed a 8.5 million EUR funding round where the EIC Fund participated and was joined by an international consortium of family offices and private investors. “I believe Ilya is at the forefront of science by developing what can be the next advancement in biologics, tissue regeneration and immunology. The management’s decision to […]

AstraZeneca offers ”one-off” business mentoring sessions for selected startups that are aspiring business and collaboration with the pharma industry. The application period for the mentoring program is open now and applicants all around Finland are welcome, reports Business Tampere. A unique opportunity “This is a unique opportunity and Tampere is the only location in Finland […]